|
|
|
Real Estate News Releases
|
(CHARTPOPPERS.COM, December 02, 2009 ) The Consolidated Investment Analysis on Siemens (NYSE: SI) will be in particular interest to other competing companys within in its sector, such as Merck & Co. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ) and GlaxoSmithKline plc. (NYSE: GSK)
Point Roberts, WA - Chartpoppers.com announces an investment report featuring company Pfizer Inc. (NYSE:PFE)
Pfizer Inc. is a research-based, global pharmaceutical company. The Company discovers, develops, manufactures and markets prescription medicines for humans and animals. It operates in two business segments: Pharmaceutical and Animal Health. Pfizer also operates several other businesses, including the manufacture of gelatin capsules, contract manufacturing and bulk pharmaceutical chemicals
Recent News on Pfizer Inc. (NYSE:PFE)
TRENTON, N.J. (AP) -- Pfizer Inc. will spend up to $115 million for rights to an Israeli biotech company's experimental drug and its promising technology for making that drug and others in carrot cells.
The world's biggest drugmaker said Tuesday its deal with Protalix BioTherapeutics Inc. involves a "groundbreaking" technology, the first to use plant cells to make protein-based drugs, that would be safer than the animal cells now used by biotech companies.
The deal also gives Pfizer worldwide rights, except in Israel, to sell a genetically engineered drug called taliglucerase alfa to treat a rare inherited condition called Gaucher's disease. Caused by deficiency of a particular enzyme, it damages the liver and bone marrow, sometimes leading to death.
"Either one, on their own, would be great," said David Simmons, head of Pfizer's established products business, referring to the technology and the drug covered by the deal.
Dr. David Aviezer, chief executive of Protalix, said his company expects by month's end to complete its submission of data to the U.S. Food and Drug Administration, from which it is seeking approval to sell taliglucerase alfa. The drug produces the enzyme -- a type of protein that triggers a biochemical reaction -- that's deficient in Gaucher's patients.
To view the Consolidated Investment Analysis on Pfizer Inc. (NYSE:PFE) Please visit the stock pulse page at www.chartpoppers.com
In the report chartpoppers.com covers a recent Financial Summary, Analyst Consensus, Technical Analysis, Comparative Analysis and Insider Trading Activity.
The full report is available at www.chartpoppers.com
Chartpoppers.com is a market research and investment commentary provider. Chartpoppers.com aims to bring undervalued, up and coming companies into the sight of both experienced and non-experienced investors. We try to help investors, at whatever stage in their careers, to get a grasp on the necessary financial data that they need in order to make a educated investment decision. From our daily trading ideas to a in depth coverage of whatÂ’s going on in the markets, we are sure that chartpoppers.com is exactly what you need in order succeed.
For More information please visit us at www.chartpoppers.com
Chartpoppers.com Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. ChartPoppers.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
CHARTPOPPERS.COM
Paul Marek
6047245332
info@chartpoppers.com 
|
|
|
|
Real Estate News by Sector
|
|
|
|
|
